Overview of the ACORN Trial

The ACORN trial investigates the safety profile of two commonly used antibiotics, piperacillin-tazobactam (PipTazo) and cefepime, in hospitalized adults with suspected infections. This trial addresses a critical concern regarding potential acute kidney injury (AKI) and neurologic dysfunction associated with these medications. The study involves a pragmatic, open-label, randomized design, enrolling over 2,500 patients across emergency and intensive care settings, which helps ensure robust and clinically relevant results. The primary aim is to determine if one antibiotic leads to better renal outcomes or reduced rates of neurologic complications in this patient population.